RU2005127216A - Новая кристаллическая модификация 2-(3, 5-бис-трифторметилфенил)-n-[6-(1, 1-диоксо-1-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиримидин-3-ил]-n-метилизобутирамида - Google Patents

Новая кристаллическая модификация 2-(3, 5-бис-трифторметилфенил)-n-[6-(1, 1-диоксо-1-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиримидин-3-ил]-n-метилизобутирамида Download PDF

Info

Publication number
RU2005127216A
RU2005127216A RU2005127216/04A RU2005127216A RU2005127216A RU 2005127216 A RU2005127216 A RU 2005127216A RU 2005127216/04 A RU2005127216/04 A RU 2005127216/04A RU 2005127216 A RU2005127216 A RU 2005127216A RU 2005127216 A RU2005127216 A RU 2005127216A
Authority
RU
Russia
Prior art keywords
thiomorpholin
dioxo
methylphenyl
fluoro
bis
Prior art date
Application number
RU2005127216/04A
Other languages
English (en)
Other versions
RU2330022C2 (ru
Inventor
Торстен ХОФФМАНН (DE)
Торстен Хоффманн
Фабинне ХОФФМАНН-ЭМЕРИ (DE)
Фабинне ХОФФМАНН-ЭМЕРИ
Сон НИКК (CH)
Соня НИКК
Урс ШВИТТЕР (CH)
Урс ШВИТТЕР
Пиус ВАЛЬДМАЙЕР (CH)
Пиус ВАЛЬДМАЙЕР
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU2005127216A publication Critical patent/RU2005127216A/ru
Application granted granted Critical
Publication of RU2330022C2 publication Critical patent/RU2330022C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Claims (6)

1. Новая кристаллическая модификация 2-(3,5-бис-трифторметилфенил)-N-[6-(1,1-диоксо-1λ6-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиридин-3-ил]-N-метилизобутирамида, отличающаяся следующими параметрами рентгеновской дифрактограммы, полученной с использованием CuKα излучения, при 2θ (угол 2 тэта): 4,5, 6,4, 7,5, 7,7, 8,0, 8,2, 10,0, 10,2, 10,9, 11,1, 12,9, 13,4, 14,0, 14,5, 15,1, 15,6, 16,2, 16,5, 17,3, 17,5, 18,0, 18,9, 19,3, 19,5, 19,9, 20,1, 20,6, 21,0, 21,4, 22,7, 23,1 и 23,6, а также инфракрасным спектром с характеристическими полосами при 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082,999, 943, 893, 868, 860, 782, 705, 684 см-1, и обладающая экстраполированной температурой плавления по данным дифференциальной сканирующей калориметрии (ДСК), составляющей 137,2°С.
2. Применение кристаллической модификации 2-(3,5-бис-трифторметилфенил)-N-[6-(1,1-диоксо-1λ6-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиридин-3-ил]-N-метилизобутирамида по п.1 для получения лекарственных средств для лечения расстройств центральной нервной системы.
3. Применение кристаллической модификации 2-(3,5-бис-трифторметилфенил)-N-[6-(1,1-диоксо-1λ6-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиридин-3-ил]-N-метилизобутирамида по п.2 для лечения мигрени, прогрессирующего деформирующего артрита (ревматоидного артрита), астмы, бронхиальной гиперреактивности, воспалительного заболевания желудочно-кишечного тракта или для лечения заболеваний, включающих болезнь Паркинсона, беспокойство, депрессию, страх, тревогу, боль, головную боль, болезнь Альцгеймера, рассеянный склероз, отек, аллергический ринит, болезнь Крона, травмы глаз, воспалительные заболевания глаз, психоз, морскую болезнь; тошноту, возникающую при езде или в полете, рвоту, непроизвольное мочеиспускание (энурез), психоиммунологические или психосоматические нарушения или расстройства, рак, синдром отмены у лиц, употреблявших наркотические лекарственные средства, седативные средства или никотин, травматические повреждения мозга или доброкачественная гиперплазия предстательной железы.
4. Применение кристаллической модификации 2-(3,5-бис-трифторметилфенил)-N-[6-(1,1-диоксо-1λ6-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиридин-3-ил]-N-метилизобутирамида по пп.2 и 3 для лечения депрессии.
5. Фармацевтически приемлемая композиция, включающая кристаллическую модификацию 2-(3,5-бис-трифторметилфенил)-N-[6-(1,1-диоксо-1λ6-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиридин-3-ил]-N-метилизобутирамида по п.1 и фармацевтически приемлемый носитель.
6. Фармацевтически приемлемая композиция по п.5, где кристаллическую модификацию 2-(3,5-бис-трифторметилфенил)-N-[6-(1,1-диоксо-1λ6-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиридин-3-ил]-N-метилизобутирамида вводят в виде порошка в желатиновых капсулах.
RU2005127216/04A 2003-01-31 2004-01-23 НОВАЯ КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ 2-(3, 5-БИС-ТРИФТОРМЕТИЛФЕНИЛ)-N-[6-(1, 1-ДИОКСО-1 λ6-ТИОМОРФОЛИН-4-ИЛ)-4-(4-ФТОР-2-МЕТИЛФЕНИЛ)ПИРИДИН-3-ИЛ]-N-МЕТИЛИЗОБУТИРАМИДА RU2330022C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002134.9 2003-01-31
EP03002134 2003-01-31

Publications (2)

Publication Number Publication Date
RU2005127216A true RU2005127216A (ru) 2006-04-10
RU2330022C2 RU2330022C2 (ru) 2008-07-27

Family

ID=32798734

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005127216/04A RU2330022C2 (ru) 2003-01-31 2004-01-23 НОВАЯ КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ 2-(3, 5-БИС-ТРИФТОРМЕТИЛФЕНИЛ)-N-[6-(1, 1-ДИОКСО-1 λ6-ТИОМОРФОЛИН-4-ИЛ)-4-(4-ФТОР-2-МЕТИЛФЕНИЛ)ПИРИДИН-3-ИЛ]-N-МЕТИЛИЗОБУТИРАМИДА

Country Status (28)

Country Link
US (1) US7160881B2 (ru)
EP (1) EP1592428B1 (ru)
JP (1) JP5026702B2 (ru)
KR (1) KR100700421B1 (ru)
CN (1) CN100562320C (ru)
AR (1) AR042980A1 (ru)
AT (1) ATE366576T1 (ru)
AU (1) AU2004208483B8 (ru)
BR (1) BRPI0406702A (ru)
CA (1) CA2514037C (ru)
CL (1) CL2004000150A1 (ru)
CO (1) CO5580750A2 (ru)
DE (1) DE602004007486T2 (ru)
ES (1) ES2290666T3 (ru)
GT (1) GT200400009A (ru)
HR (1) HRP20050664A2 (ru)
IL (1) IL169600A (ru)
MX (1) MXPA05008171A (ru)
MY (1) MY135785A (ru)
NO (1) NO20053431L (ru)
NZ (1) NZ541243A (ru)
PA (1) PA8594601A1 (ru)
PE (1) PE20040944A1 (ru)
PL (1) PL378404A1 (ru)
RU (1) RU2330022C2 (ru)
TW (1) TWI293294B (ru)
WO (1) WO2004067007A1 (ru)
ZA (1) ZA200505567B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
CN102639536B (zh) * 2009-08-27 2015-03-18 尼尔医疗有限公司 吡啶衍生物的无水晶型
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ES2164758T3 (es) 1993-12-29 2002-03-01 Merck Sharp & Dohme Derivados de morfolina sustituidos y su uso como agentes terapeuticos.
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
DE60210760T2 (de) * 2001-04-23 2006-11-23 F. Hoffmann-La Roche Ag Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
GT200400009A (es) 2004-12-01
AR042980A1 (es) 2005-07-13
TWI293294B (en) 2008-02-11
US20040186100A1 (en) 2004-09-23
JP5026702B2 (ja) 2012-09-19
RU2330022C2 (ru) 2008-07-27
NO20053431D0 (no) 2005-07-14
MY135785A (en) 2008-06-30
PE20040944A1 (es) 2004-12-14
ZA200505567B (en) 2007-05-30
CO5580750A2 (es) 2005-11-30
PA8594601A1 (es) 2004-09-16
NO20053431L (no) 2005-10-05
ES2290666T3 (es) 2008-02-16
KR20050096964A (ko) 2005-10-06
CN100562320C (zh) 2009-11-25
AU2004208483B2 (en) 2008-03-06
DE602004007486D1 (de) 2007-08-23
MXPA05008171A (es) 2005-10-05
CA2514037A1 (en) 2004-08-12
IL169600A (en) 2010-11-30
EP1592428B1 (en) 2007-07-11
ATE366576T1 (de) 2007-08-15
BRPI0406702A (pt) 2005-12-20
CA2514037C (en) 2012-03-13
CN1744900A (zh) 2006-03-08
CL2004000150A1 (es) 2005-01-07
NZ541243A (en) 2008-04-30
HRP20050664A2 (en) 2006-12-31
AU2004208483A1 (en) 2004-08-12
JP2006514999A (ja) 2006-05-18
WO2004067007A1 (en) 2004-08-12
US7160881B2 (en) 2007-01-09
AU2004208483B8 (en) 2008-04-03
TW200510358A (en) 2005-03-16
EP1592428A1 (en) 2005-11-09
DE602004007486T2 (de) 2008-04-30
KR100700421B1 (ko) 2007-03-28
PL378404A1 (pl) 2006-04-03

Similar Documents

Publication Publication Date Title
AU2022200811B2 (en) A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid
US20230348381A1 (en) Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
TWI361691B (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2277149T3 (es) Derivados de piridina como moduladores de los receptores cb2.
CN101778819A (zh) 用作cb2激动剂的吲哚茚满酰胺化合物和方法
US20020107257A1 (en) Treatments for restless legs syndrome
JP2000501728A (ja) タキキニン受容体の拮抗薬としての３―ベンジルアミノピロリジン及び３―ベンジルアミノピペリジン
TW200410946A (en) Compounds
TW201506012A (zh) 作爲單胺氧化酶（ｍａｏ）抑制劑之經取代之萘啶及喹啉化合物
US20080280952A1 (en) Pyridine Derivatives as Connabinoid Receptor Modulators
ES2313304T3 (es) Derivados de piridina y su uso como moduladores del receptor cb2.
HUP0401201A2 (hu) Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására
JP2008521855A (ja) 新規ピリドチエノピリミジン誘導体
WO2022123232A1 (en) Pharmaceutical composition comprising psilocybin or its polymorphs
RU2005127216A (ru) Новая кристаллическая модификация 2-(3, 5-бис-трифторметилфенил)-n-[6-(1, 1-диоксо-1-тиоморфолин-4-ил)-4-(4-фтор-2-метилфенил)пиримидин-3-ил]-n-метилизобутирамида
CA2452502A1 (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide
JP2005500354A5 (ru)
TW200824689A (en) Novel compounds
JP2010529130A5 (ru)
RU2004127585A (ru) Кристаллическая натриевая соль парекоксиба
RU2006114024A (ru) Полиморфная форма 3-фенилсульфонил-8-пиперазин-1-ил-хинолина
JP2011509296A5 (ru)
PL366060A1 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists
JP2011520964A (ja) ニコチン性アセチルコリン受容体活性を有する化合物を用いる末梢感覚神経喪失の治療方法
TW200410698A (en) Methods of treating patients suffering from restless legs syndrome or related disorders

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110124